ImageneBio (IMA) Current Deferred Revenue (2020 - 2024)

ImageneBio has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $650000.0 for Q4 2024.

• Current Deferred Revenue for Q4 2024 came in at $650000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $650000.0 (changed N/A YoY), and the FY2024 annual result was $650000.0, changed N/A from the prior year.
• Current Deferred Revenue came in at $650000.0 for Q4 2024 at ImageneBio, down from $700000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $22.6 million in Q3 2021 to a low of $650000.0 in Q4 2024.
• The 5-year median for Current Deferred Revenue is $14.4 million (2022), against an average of $12.0 million.
• Across the five-year window, Current Deferred Revenue tumbled 94.56% in 2023 and increased 6.22% in 2024, its largest moves.
• ImageneBio's Current Deferred Revenue stood at $20.6 million in 2020, then retreated by 17.08% to $17.1 million in 2021, then tumbled by 46.2% to $9.2 million in 2022, then slumped by 92.84% to $659000.0 in 2023, then retreated by 1.37% to $650000.0 in 2024.
• The last three Current Deferred Revenue figures came in at $650000.0 (Q4 2024), $700000.0 (Q3 2024), and $659000.0 (Q3 2023), per Business Quant data.